Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Basic): 2010-2025

Historic EPS (Basic) for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$0.13.

  • Lineage Cell Therapeutics' EPS (Basic) fell 550.00% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 141.67%. This contributed to the annual value of -$0.09 for FY2024, which is 25.00% up from last year.
  • Lineage Cell Therapeutics' EPS (Basic) amounted to -$0.13 in Q3 2025, which was down 0.00% from -$0.13 recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' EPS (Basic) peaked at -$0.01 during Q4 2024, and registered a low of -$0.17 during Q4 2021.
  • In the last 3 years, Lineage Cell Therapeutics' EPS (Basic) had a median value of -$0.03 in 2024 and averaged -$0.05.
  • Over the last 5 years, Lineage Cell Therapeutics' EPS (Basic) had its largest YoY gain of 83.33% in 2021, and its largest YoY loss of 1,800.00% in 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' EPS (Basic) (Quarterly) stood at -$0.17 in 2021, then skyrocketed by 82.35% to -$0.03 in 2022, then remained steady at -$0.03 in 2023, then spiked by 66.67% to -$0.01 in 2024, then slumped by 550.00% to -$0.13 in 2025.
  • Its EPS (Basic) was -$0.13 in Q3 2025, compared to -$0.13 in Q2 2025 and -$0.02 in Q1 2025.